ADMA Biologics: A Compelling GARP Stock For Biotech Investors
ADMA Biologics targets immune-compromised patients with plasma-derived products. They have three FDA-approved drugs and operate in a promising immunoglobulin market.
View signal analysisCompany intelligence
ADMA
ADMA Biologics, Inc. · NASDAQ · Healthcare
Price$9.62-1.08% · −$0.11
Market cap2.23BEquity value
P / E13.5Trailing ratio
Volume163.44KLatest session
Market data
TradingViewADMA price chart
Related signals
1 min delayedLatest ADMA price-moving signals
Browse public ADMA signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Research